The neonatal and juvenile pig in pediatric drug discovery and development

M Ayuso; L Buyssens; M Stroe; A Valenzuela; Karel Allegaert; A Smits; P Annaert; A Mulder; S Carpentier; C Van Ginneken; S Van Cruchten

doi:10.3390/pharmaceutics13010044

The neonatal and juvenile pig in pediatric drug discovery and development

M Ayuso, L Buyssens, M Stroe, A Valenzuela, Karel Allegaert, A Smits, P Annaert, A Mulder, S Carpentier, C Van Ginneken, S Van Cruchten

Pharmacy

Research output: Contribution to journal › Review article › Academic › peer-review

25 Citations (Scopus)

18 Downloads (Pure)

Abstract

Pharmacotherapy in pediatric patients is challenging in view of the maturation of organ systems and processes that affect pharmacokinetics and pharmacodynamics. Especially for the youngest age groups and for pediatric-only indications, neonatal and juvenile animal models can be useful to assess drug safety and to better understand the mechanisms of diseases or conditions. In this respect, the use of neonatal and juvenile pigs in the field of pediatric drug discovery and development is promising, although still limited at this point. This review summarizes the comparative postnatal development of pigs and humans and discusses the advantages of the juvenile pig in view of developmental pharmacology, pediatric diseases, drug discovery and drug safety testing. Furthermore, limitations and unexplored aspects of this large animal model are covered. At this point in time, the potential of the neonatal and juvenile pig as nonclinical safety models for pediatric drug development is underexplored.

Original language	English
Article number	44
Pages (from-to)	1-36
Number of pages	36
Journal	Pharmaceutics
Volume	13
Issue number	1
DOIs	https://doi.org/10.3390/pharmaceutics13010044
Publication status	Published - 2021

Bibliographical note

Funding Information:
This research was funded by the European Union’s Horizon 2020 program under Grant Agreement No. 777554, the special research fund of the University of Antwerp under grant Nos. 26733, 34479 and 42354, and by the Research Foundation Flanders (FWO) under grant No. G0D0520N, the Herculesstichting under grant No. AUHA/13/006 and by the Ellegaard Göttingen Minipigs Research Foundation under grant No. 34237.

Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.

Research programs

EMC OR-01

Access to Document

10.3390/pharmaceutics13010044Licence: CC BY

Repub_133764_O-A.pdfFinal published version, 6.8 MBLicence: CC BY

Cite this

@article{016c1d9ef1f7419f8cff2d1eb6ce9e00,

title = "The neonatal and juvenile pig in pediatric drug discovery and development",

abstract = "Pharmacotherapy in pediatric patients is challenging in view of the maturation of organ systems and processes that affect pharmacokinetics and pharmacodynamics. Especially for the youngest age groups and for pediatric-only indications, neonatal and juvenile animal models can be useful to assess drug safety and to better understand the mechanisms of diseases or conditions. In this respect, the use of neonatal and juvenile pigs in the field of pediatric drug discovery and development is promising, although still limited at this point. This review summarizes the comparative postnatal development of pigs and humans and discusses the advantages of the juvenile pig in view of developmental pharmacology, pediatric diseases, drug discovery and drug safety testing. Furthermore, limitations and unexplored aspects of this large animal model are covered. At this point in time, the potential of the neonatal and juvenile pig as nonclinical safety models for pediatric drug development is underexplored.",

author = "M Ayuso and L Buyssens and M Stroe and A Valenzuela and Karel Allegaert and A Smits and P Annaert and A Mulder and S Carpentier and {Van Ginneken}, C and {Van Cruchten}, S",

note = "Funding Information: This research was funded by the European Union{\textquoteright}s Horizon 2020 program under Grant Agreement No. 777554, the special research fund of the University of Antwerp under grant Nos. 26733, 34479 and 42354, and by the Research Foundation Flanders (FWO) under grant No. G0D0520N, the Herculesstichting under grant No. AUHA/13/006 and by the Ellegaard G{\"o}ttingen Minipigs Research Foundation under grant No. 34237. Publisher Copyright: {\textcopyright} 2020 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

doi = "10.3390/pharmaceutics13010044",

language = "English",

volume = "13",

pages = "1--36",

journal = "Pharmaceutics",

issn = "1999-4923",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "1",

}

TY - JOUR

T1 - The neonatal and juvenile pig in pediatric drug discovery and development

AU - Ayuso, M

AU - Buyssens, L

AU - Stroe, M

AU - Valenzuela, A

AU - Allegaert, Karel

AU - Smits, A

AU - Annaert, P

AU - Mulder, A

AU - Carpentier, S

AU - Van Ginneken, C

AU - Van Cruchten, S

N1 - Funding Information: This research was funded by the European Union’s Horizon 2020 program under Grant Agreement No. 777554, the special research fund of the University of Antwerp under grant Nos. 26733, 34479 and 42354, and by the Research Foundation Flanders (FWO) under grant No. G0D0520N, the Herculesstichting under grant No. AUHA/13/006 and by the Ellegaard Göttingen Minipigs Research Foundation under grant No. 34237. Publisher Copyright: © 2020 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2021

Y1 - 2021

N2 - Pharmacotherapy in pediatric patients is challenging in view of the maturation of organ systems and processes that affect pharmacokinetics and pharmacodynamics. Especially for the youngest age groups and for pediatric-only indications, neonatal and juvenile animal models can be useful to assess drug safety and to better understand the mechanisms of diseases or conditions. In this respect, the use of neonatal and juvenile pigs in the field of pediatric drug discovery and development is promising, although still limited at this point. This review summarizes the comparative postnatal development of pigs and humans and discusses the advantages of the juvenile pig in view of developmental pharmacology, pediatric diseases, drug discovery and drug safety testing. Furthermore, limitations and unexplored aspects of this large animal model are covered. At this point in time, the potential of the neonatal and juvenile pig as nonclinical safety models for pediatric drug development is underexplored.

AB - Pharmacotherapy in pediatric patients is challenging in view of the maturation of organ systems and processes that affect pharmacokinetics and pharmacodynamics. Especially for the youngest age groups and for pediatric-only indications, neonatal and juvenile animal models can be useful to assess drug safety and to better understand the mechanisms of diseases or conditions. In this respect, the use of neonatal and juvenile pigs in the field of pediatric drug discovery and development is promising, although still limited at this point. This review summarizes the comparative postnatal development of pigs and humans and discusses the advantages of the juvenile pig in view of developmental pharmacology, pediatric diseases, drug discovery and drug safety testing. Furthermore, limitations and unexplored aspects of this large animal model are covered. At this point in time, the potential of the neonatal and juvenile pig as nonclinical safety models for pediatric drug development is underexplored.

UR - http://www.scopus.com/inward/record.url?scp=85099463571&partnerID=8YFLogxK

U2 - 10.3390/pharmaceutics13010044

DO - 10.3390/pharmaceutics13010044

M3 - Review article

SN - 1999-4923

VL - 13

SP - 1

EP - 36

JO - Pharmaceutics

JF - Pharmaceutics

IS - 1

M1 - 44

ER -

The neonatal and juvenile pig in pediatric drug discovery and development

Abstract

Bibliographical note

Research programs

Access to Document

Other files and links

Fingerprint

Cite this